In what could be termed a significant medical breakthrough, a study from the University of California San Diego School of Medicine has revealed that an already FDA-approved breast cancer medication may find new life as a treatment for a rare form of appendix cancer known as peritoneal mucinous carcinomatosis (PMC). According to the Journal of Clinical Oncology, the drug palbociclib demonstrated noteworthy efficacy in halting the progression of the disease, offering a glimmer of hope to patients who often grapple with limited treatment options, as detailed by UC San Diego Health news release.
This discovery highlights the drug's potential for new uses beyond its original purpose. In a clinical trial with 16 participants, researchers observed tumor stabilization and lower blood tumor markers. This finding has attracted attention because it suggests the existing medication could be repurposed for a specific cancer type, avoiding the lengthy process of developing a new drug and going through FDA approval again. Led by experts like Dr. Andrew Lowy and Dr. Shumei Kato from UC San Diego Health, the study noted particularly positive results in tumors with GNAS gene mutations, opening the door for targeted therapies for this condition.
With less than 1% of gastrointestinal cancers being attributed to the appendix and with fewer than 2,000 cases estimated to occur annually in the U.S. by the American Cancer Society, appendix cancer stands as a sporadic disease. Despite this rarity, the research embodies a crucial leap forward for those affected, with significant improvements observed in over 80% of patients exhibiting the specific genetic mutation.
The implications of this study are amplified by the support of the Moores Cancer Center at UC San Diego Health, an institution renowned for its leading-edge treatment options and as the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in the region, says Diane Simeone, MD, the center's director. As this research was not conducted in a silo but rather with the assistance of multiple collaborators at UC San Diego, including the likes of Jonathan Weitz and Jay Patel, to name a few, and funding from numerous sources.
